Martin R Turner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7308477/publications.pdf

Version: 2024-02-01

243 papers	18,752 citations	17405 63 h-index	14702 127 g-index
255 all docs	255 docs citations	255 times ranked	19538 citing authors

#	Article	IF	Citations
1	Amyotrophic lateral sclerosis. Lancet, The, 2011, 377, 942-955.	6.3	2,182
2	Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry,the, 2020, 7, 875-882.	3.7	1,005
3	Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiology of Disease, 2004, 15, 601-609.	2.1	630
4	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 153-174.	1.1	607
5	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
6	Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Human Molecular Genetics, 2009, 18, 472-481.	1.4	512
7	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
8	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	4.9	454
9	Neurofilament light chain. Neurology, 2015, 84, 2247-2257.	1.5	412
10	Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology, The, 2009, 8, 94-109.	4.9	391
11	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	4.9	342
12	Exome-wide Rare Variant Analysis Identifies TUBA4A Mutations Associated with Familial ALS. Neuron, 2014, 84, 324-331.	3.8	308
13	Extracellular vesicles in neurodegenerative disease â€" pathogenesis to biomarkers. Nature Reviews Neurology, 2016, 12, 346-357.	4.9	299
14	A proposed staging system for amyotrophic lateral sclerosis. Brain, 2012, 135, 847-852.	3.7	296
15	A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978.	0.7	268
16	Diffusion imaging of whole, post-mortem human brains on a clinical MRI scanner. NeuroImage, 2011, 57, 167-181.	2.1	239
17	Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain, 2011, 134, 3470-3479.	3.7	229
18	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	9.4	218

#	Article	IF	Citations
19	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
20	C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Stem Cells, 2016, 34, 2063-2078.	1.4	195
21	Amyotrophic lateral sclerosis in an urban setting. Journal of Neurology, 2006, 253, 1642-1643.	1.8	181
22	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 400-403.	4.9	156
23	Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Molecular and Cellular Neurosciences, 2013, 53, 34-41.	1.0	156
24	Autoimmune disease preceding amyotrophic lateral sclerosis. Neurology, 2013, 81, 1222-1225.	1.5	156
25	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	4.9	152
26	Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain, 2014, 137, 2546-2555.	3.7	151
27	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.5	148
28	The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 439-442.	2.3	140
29	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 570-579.	0.9	138
30	Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 19-32.	1.1	135
31	Neuroimaging in amyotrophic lateral sclerosis. Biomarkers in Medicine, 2012, 6, 319-337.	0.6	133
32	Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology, 2014, 76, 643-657.	2.8	133
33	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	129
34	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2017, 140, 887-897.	3.7	126
35	Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 215-221.	0.9	124
36	Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 245-250.	2.3	121

#	Article	IF	Citations
37	<scp>CSF</scp> neurofilament light chain reflects corticospinal tract degeneration in <scp>ALS</scp>. Annals of Clinical and Translational Neurology, 2015, 2, 748-755.	1.7	118
38	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	0.9	118
39	Defective cholesterol metabolism in amyotrophic lateral sclerosis. Journal of Lipid Research, 2017, 58, 267-278.	2.0	115
40	Oculomotor Dysfunction in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 857.	4.9	112
41	Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 279-284.	1.1	111
42	Identification of distinct circulating exosomes in Parkinson's disease. Annals of Clinical and Translational Neurology, 2015, 2, 353-361.	1.7	111
43	Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Annals of Neurology, 2018, 83, 258-268.	2.8	107
44	Genetic screening in sporadic ALS and FTD. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1042-1044.	0.9	105
45	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.5	105
46	The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 667-673.	0.9	104
47	Towards a TDP-43-Based Biomarker for ALS and FTLD. Molecular Neurobiology, 2018, 55, 7789-7801.	1.9	100
48	The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2018, 17, 953-961.	1.4	100
49	Advances in motor neurone disease. Journal of the Royal Society of Medicine, 2014, 107, 14-21.	1.1	93
50	Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nature Reviews Neurology, 2011, 7, 631-638.	4.9	92
51	The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2010, 294, 81-85.	0.3	87
52	Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2016, 127, 2643-2660.	0.7	87
53	Mimics and chameleons in motor neurone disease. Practical Neurology, 2013, 13, 153-164.	0.5	84
54	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.1	84

#	Article	IF	Citations
55	Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain, 2019, 142, 586-605.	3.7	84
56	Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathologica Communications, 2017, 5, 13.	2.4	83
57	Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 15-21.	1.4	82
58	Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 580-588.	0.9	82
59	A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology, 2014, 83, 1492-1499.	1.5	80
60	Non-neuronal cells in amyotrophic lateral sclerosis â€" from pathogenesis to biomarkers. Nature Reviews Neurology, 2021, 17, 333-348.	4.9	78
61	Seasonal variation in Guillain-BarrÃ© syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1196-1201.	0.9	77
62	Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 45-49.	0.9	75
63	Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2017, 14, 11-23.	2.1	72
64	Some difficult decisions in ALS/MND. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 339-343.	2.3	71
65	Diagnostic Accuracy of Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis. Academic Radiology, 2013, 20, 1099-1106.	1.3	70
66	Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 510-518.	0.9	69
67	CSF chitinase proteins in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1215-1220.	0.9	66
68	Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain, 2012, 135, 2883-2891.	3.7	65
69	Mind the gap: The mismatch between clinical and imaging metrics in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 524-529.	1.1	65
70	The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 414-425.	1.1	65
71	Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 101-111.	1.1	65
72	Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 395-398.	0.9	62

#	Article	IF	Citations
73	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1000-1004.	0.9	62
74	Defining causality in COVID-19 and neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 811-812.	0.9	62
75	Fractional Anisotropy in the Posterior Limb of the Internal Capsule and Prognosis in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2012, 69, 1493.	4.9	60
76	What Does Imaging Reveal About the Pathology of Amyotrophic Lateral Sclerosis?. Current Neurology and Neuroscience Reports, 2015, 15, 45.	2.0	60
77	Myelin imaging in amyotrophic and primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 562-573.	1.1	59
78	ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiology of Aging, 2018, 71, 266.e1-266.e10.	1.5	59
79	Pattern of spread and prognosis in lower limb-onset ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 369-373.	2.3	58
80	Altered cortical betaâ€band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis. Human Brain Mapping, 2017, 38, 237-254.	1.9	58
81	Magnetoencephalography. Practical Neurology, 2014, 14, 336-343.	0.5	57
82	Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: An (¹¹C)â€flumazenil PET study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 43-49.	2.3	56
83	Multiple Kernel Learning Captures a Systems-Level Functional Connectivity Biomarker Signature in Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e85190.	1.1	55
84	Imaging Cerebral Activity in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1148.	1.1	55
85	Advances in the application of MRI to amyotrophic lateral sclerosis. Expert Opinion on Medical Diagnostics, 2010, 4, 483-496.	1.6	54
86	Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 303-309.	1.1	53
87	Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. Neurology, 2013, 80, 610-615.	1.5	50
88	The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 456-463.	1.1	49
89	Psychiatric disorders prior to amyotrophic lateral sclerosis. Annals of Neurology, 2016, 80, 935-938.	2.8	49
90	Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS. Journal of the Neurological Sciences, 2010, 288, 45-48.	0.3	48

#	Article	IF	Citations
91	Low index-to-ring finger length ratio in sporadic ALS supports prenatally defined motor neuronal vulnerability. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 635-7.	0.9	48
92	Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle and Nerve, 2015, 51, 14-18.	1.0	48
93	Dissecting the pathobiology of altered MRI signal in amyotrophic lateral sclerosis: A post mortem whole brain sampling strategy for the integration of ultra-high-field MRI and quantitative neuropathology. BMC Neuroscience, 2018, 19, 11.	0.8	47
94	Clinical Trials in ALS: An Overview. Seminars in Neurology, 2001, 21, 167-176.	0.5	45
95	Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 343-347.	2.3	45
96	Tools and talk: An evolutionary perspective on the functional deficits associated with amyotrophic lateral sclerosis. Muscle and Nerve, 2014, 49, 469-477.	1.0	45
97	Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. Genome Research, 2017, 27, 165-173.	2.4	44
98	Cortical involvement in four cases of primary lateral sclerosis using [11C]-flumazenil PET. Journal of Neurology, 2007, 254, 1033-1036.	1.8	42
99	Diffusion Tensor Imaging in Sporadic and Familial (D90A SOD1) Forms of Amyotrophic Lateral Sclerosis. Archives of Neurology, 2009, 66, 109-15.	4.9	42
100	Trends in death certification for multiple sclerosis, motor neuron disease, Parkinsonâ€™s disease and epilepsy in English populations 1979â€“2006. Journal of Neurology, 2010, 257, 706-715.	1.8	41
101	Geographical Clustering of Amyotrophic Lateral Sclerosis in South-East England: A Population Study. Neuroepidemiology, 2009, 32, 81-88.	1.1	40
102	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
103	Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1250-1258.	0.9	39
104	Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair. Human Molecular Genetics, 2020, 29, 2200-2217.	1.4	39
105	Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 786-788.	4.9	38
106	The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 569-575.	1.1	38
107	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	3.7	38
108	Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis. Annals of Neurology, 2003, 54, 130-134.	2.8	37

#	Article	IF	Citations
109	Amyotrophic lateral sclerosis and cancer: A register-based study in Sweden. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 362-368.	1.1	37
110	Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T applied to amyotrophic lateral sclerosis. NeuroImage, 2020, 222, 117216.	2.1	37
111	Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 1479-1489.	0.7	36
112	UFLCâ€Derived CSF Extracellular Vesicle Origin and Proteome. Proteomics, 2018, 18, e1800257.	1.3	36
113	Amyotrophic lateral sclerosis: the complex path to precision medicine. Journal of Neurology, 2018, 265, 2454-2462.	1.8	36
114	Relative preservation of triceps over biceps strength in upper limb-onset ALS: the â€˜split elbowâ€™. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 730-733.	0.9	34
115	Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis. Brain Communications, 2020, 2, fcaa053.	1.5	34
116	Functional vitamin B12 deficiency. Practical Neurology, 2009, 9, 37-45.	0.5	33
117	Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. Brain Communications, 2021, 3, fcab168.	1.5	33
118	Large-scale pathways-based association study in amyotrophic lateral sclerosis. Brain, 2007, 130, 2292-2301.	3.7	32
119	T₂-Weighted MRI Detects Presymptomatic Pathology in the SOD1 Mouse Model of ALS. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 785-793.	2.4	32
120	Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study. JMIR MHealth and UHealth, 2019, 7, e13433.	1.8	32
121	Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 244-246.	0.9	31
122	Quantitative FLAIR MRI in Amyotrophic Lateral Sclerosis. Academic Radiology, 2017, 24, 1187-1194.	1.3	31
123	An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. Neurobiology of Disease, 2020, 144, 105050.	2.1	30
124	Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Communications, 2022, 4, fcac029.	1.5	29
125	Management of sialorrhoea in motor neuron disease: A survey of current UK practice. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 521-527.	1.1	28
126	CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2014, 2, 66.	2.4	28

#	Article	IF	Citations
127	When to consider thyroid dysfunction in the neurology clinic. Practical Neurology, 2009, 9, 145-156.	0.5	27
128	Quantitative patterns of motor cortex proteinopathy across ALS genotypes. Acta Neuropathologica Communications, 2020, 8, 98.	2.4	27
129	CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis. Clinical Proteomics, 2020, 17, 31.	1.1	27
130	A case of celiac disease mimicking amyotrophic lateral sclerosis. Nature Clinical Practice Neurology, 2007, 3, 581-584.	2.7	26
131	Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 285-291.	1.1	26
132	Increased cerebral functional connectivity in ALS. Neurology, 2018, 90, e1418-e1424.	1.5	26
133	Cerebellar tract alterations in PLS and ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 281-284.	1.1	26
134	CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1296-1306.	1.7	26
135	Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 227-234.	0.9	26
136	Detection and quantification of novel Câ€terminal TDPâ€43 fragments in ALSâ€TDP. Brain Pathology, 2021, 31, e12923.	2.1	26
137	Imaging as a biomarker in drug discovery for Alzheimerâ€™s disease: is MRI a suitable technology?. Alzheimer's Research and Therapy, 2014, 6, 51.	3.0	24
138	Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 75-81.	0.9	24
139	Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis. Brain, 2010, 133, 3470-3479.	3.7	22
140	Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 487-493.	1.1	22
141	Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 422-435.	0.9	22
142	The Digital Brain Bank, an open access platform for post-mortem imaging datasets. ELife, 2022, 11, .	2.8	22
143	Comparison of two percutaneous radiological gastrostomy tubes in the nutritional management of ALS patients. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 177-181.	2.3	21
144	Increased premorbid physical activity and amyotrophic lateral sclerosis: born to run rather than run to death, or a seductive myth?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 947-947.	0.9	21

#	Article	IF	Citations
145	Neuroimaging in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 18-27.	1.1	21
146	An Eye-Tracking Version of the Trail-Making Test. PLoS ONE, 2013, 8, e84061.	1.1	21
147	A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 1-9.	1.1	20
148	Frequency and signature of somatic variants in 1461 human brain exomes. Genetics in Medicine, 2019, 21, 904-912.	1.1	20
149	MRI as a frontrunner in the search for amyotrophic lateral sclerosis biomarkers?. Biomarkers in Medicine, 2011, 5, 79-81.	0.6	19
150	Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) in the older adult. Practical Neurology, 2014, 14, 432-436.	0.5	19
151	Primary lateral sclerosis: diagnosis and management. Practical Neurology, 2020, 20, 262-269.	0.5	19
152	Voxel-Based MRI Intensitometry Reveals Extent of Cerebral White Matter Pathology in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e104894.	1.1	19
153	The association between ALS and population density: A population based study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 435-438.	2.3	18
154	A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 243-248.	1.1	18
155	Reduced cancer incidence in Huntington's disease: record linkage study clue to an evolutionary tradeâ€off?. Clinical Genetics, 2013, 83, 588-590.	1.0	17
156	Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 813-816.	0.9	17
157	Genetic testing in motor neurone disease. Practical Neurology, 2022, 22, 107-116.	0.5	17
158	Evolution of white matter damage in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 722-732.	1.7	16
159	Reversible diffusion MRI abnormalities and transient mutism after liver transplantation. Neurology, 2005, 64, 177-177.	1.5	15
160	Progressive hemiparesis (Mills syndrome) with aphasia in amyotrophic lateral sclerosis. Neurology, 2014, 82, 457-458.	1.5	15
161	Tracheostomy in motor neurone disease. Practical Neurology, 2019, 19, 467-475.	0.5	15
162	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.1	15

#	Article	IF	Citations
163	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.1	14
164	Positron emission tomography (PET) â€“ its potential to provide surrogate markers in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, 17-22.	1.4	14
165	Positron emission tomography (PET) â€“ its potential to provide surrogate markers in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, s17-s22.	1.4	13
166	The internet for self-diagnosis and prognostication in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 565-567.	2.3	13
167	Does dysfunction of the mirror neuron system contribute to symptoms in amyotrophic lateral sclerosis?. Clinical Neurophysiology, 2015, 126, 1288-1294.	0.7	13
168	Regional callosal integrity and bilaterality of limb weakness in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 396-402.	1.1	13
169	The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 563-573.	1.1	12
170	Are neurofilaments heading for the ALS clinic?. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 87, jnnp-2015-311934.	0.9	11
171	Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 570-575.	0.9	11
172	Neurophysiological features of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 11-17.	1.1	11
173	The clinical spectrum of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 3-10.	1.1	11
174	Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphoma. Journal of the Peripheral Nervous System, 2003, 8, 100-107.	1.4	10
175	A novel central motor conduction abnormality in D90A-homozygous patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2004, 29, 790-794.	1.0	10
176	Epilepsy and the subsequent risk of cerebral tumour: record linkage retrospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1041-1045.	0.9	10
177	Catastrophic hyperkalaemia following administration of suxamethonium chloride to a patient with undiagnosed amyotrophic lateral sclerosis. Clinical Medicine, 2011, 11, 292-293.	0.8	10
178	Progress and new frontiers in biomarkers for amyotrophic lateral sclerosis. Biomarkers in Medicine, 2018, 12, 693-696.	0.6	10
179	Characterising neuropsychiatric disorders in patients with COVID-19 â€“ Authors' reply. Lancet Psychiatry,the, 2020, 7, 934-935.	3.7	10
180	The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 481-482.	0.9	9

#	Article	IF	Citations
181	Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology. Neurology, 2020, 95, 595-596.	1.5	9
182	Public awareness of motor neuron disease. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 490-491.	2.3	8
183	Magnetic resonance imaging of pathological processes in rodent models of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 288-301.	2.3	8
184	What is the place of thrombolysis in acute stroke? A review of the literature and a current perspective. Clinical Medicine, 2008, 8, 253-258.	0.8	7
185	The borderland of neuromyelitis optica. Practical Neurology, 2009, 9, 335-340.	0.5	7
186	Unmasking of incipient amyotrophic lateral sclerosis by botulinum toxin therapy. Journal of Neurology, 2013, 260, 1166-1167.	1.8	7
187	Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 600-604.	1.1	7
188	The tough body at the epicentre of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 369.2-370.	0.9	7
189	Untangling neuroinflammation in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-321242.	0.9	7
190	Therapeutic non-invasive brain stimulation in amyotrophic lateral sclerosis: rationale, methods and experience. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1131-1138.	0.9	7
191	The reunification of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 122-123.	0.9	7
192	Diagnosing ALS: the Gold Coast criteria and the role of EMG. Practical Neurology, 2022, , practneurol-2021-003256.	0.5	7
193	Motor neurone disease is a clinical diagnosis. Practical Neurology, 2012, 12, 396-397.	0.5	6
194	Progressive hemiparesis in a 75-year-old man. Practical Neurology, 2015, 15, 63-71.	0.5	6
195	A wider pathological network underlying breathlessness and respiratory failure in amyotrophic lateral sclerosis. European Respiratory Journal, 2016, 47, 1632-1634.	3.1	6
196	Network Analysis of the CSF Proteome Characterizes Convergent Pathways of Cellular Dysfunction in ALS. Frontiers in Neuroscience, 2021, 15, 642324.	1.4	6
197	Creatine kinase and prognosis in amyotrophic lateral sclerosis: a literature review and multi-centre cohort analysis. Journal of Neurology, 2022, 269, 5395-5404.	1.8	6
198	Lou Gehrig and the ALS split hand. Neurology, 2015, 85, 1995-1995.	1.5	5

#	Article	IF	Citations
199	Motor neuron disease: biomarker development for an expanding cerebral syndrome. Clinical Medicine, 2016, 16, s60-s65.	0.8	5
200	Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. Expert Review of Proteomics, 2021, 18, 977-994.	1.3	5
201	Modeling seeding and neuroanatomic spread of pathology in amyotrophic lateral sclerosis. NeuroImage, 2022, 251, 118968.	2.1	5
202	Teaching Video Neuro Images : Acute Adie syndrome. Neurology, 2012, 79, e97.	1.5	4
203	Sweet food preference in amyotrophic lateral sclerosis. Practical Neurology, 2017, 17, 128-129.	0.5	4
204	Kinnier Wilsonâ€™s puzzling features of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 657-666.	0.9	4
205	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
206	Riluzole and Motor Neurone Disease. Practical Neurology, 2003, 3, 160-169.	0.5	3
207	Teaching Neuro Images : Somatic muscle fasciculations detected by electrocardiography. Neurology, 2012, 78, e19.	1.5	3
208	Unilateral leukonychia and hair depigmentation in multifocal motor neuropathy. Neurology, 2013, 81, 1800-1801.	1.5	3
209	Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 442-447.	1.1	3
210	Romberg's test no longer stands up. Practical Neurology, 2016, 16, 316-316.	0.5	3
211	Is cardiovascular fitness a risk factor for ALS?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 538-538.	0.9	3
212	Non-invasive in vivo neuropathology of the C9orf72-related ALS-FTD syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 4-5.	0.9	3
213	REM sleep physiology and selective neuronal vulnerability in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 789-790.	0.9	3
214	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.1	3
215	Starting a research post: some considerations for ward-based doctors. British Journal of Hospital Medicine, 2001, 62, 627-630.	0.3	2
216	Child Neurology: A growing skull fracture. Neurology, 2009, 72, e38.	1.5	2

#	Article	IF	Citations
217	Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 382-382.	0.9	2
218	Progressive dysphagia without dysarthria. Practical Neurology, 2013, 13, 197-197.	0.5	2
219	Peer recommendations on how to improve clinical research, and Conference wrap-up. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 67-73.	1.1	2
220	Swallowing and oropharyngeal dysphagia. Clinical Medicine, 2014, 14, 456.	0.8	2
221	The early biomarker challenge in neurodegenerative disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1190-1191.	0.9	2
222	Isolated homozygous R217X OPTN mutation causes knock-out of functional C-terminal optineurin domains and associated oligodendrogliopathy-dominant ALSâ€“TDP. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1022-1024.	0.9	2
223	Chapter 21 Disease-Modifying Therapies in Motor Neuron Disorders: The Present Position and Potential Future Developments. Blue Books of Practical Neurology, 2003, 28, 497-544.	0.1	1
224	Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 255-257.	2.3	1
225	Promoting clinical and patient-oriented research to identify the pathogenesis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 1-4.	1.1	1
226	The wisdom of neurologists. Practical Neurology, 2013, 13, 350-350.	0.5	1
227	Nutritional pathway for people with motor neurone disease. British Journal of Community Nursing, 2016, 21, 360-363.	0.2	1
228	Focal precentral gyrus involvement in osmotic demyelination. Practical Neurology, 2017, 17, 410-411.	0.5	1
229	Milestones. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1189-1189.	0.9	1
230	Grand rounds: a precious resource to be nurtured. Practical Neurology, 2020, 20, 342-344.	0.5	1
231	To Zoom or Not to Zoom: The Should I Travel Index Revisited during the Coronavirus Disease Pandemic. Annals of Neurology, 2021, 89, 1057-1058.	2.8	1
232	Delayed recovery of ulnar neuropathy due to elbow warming. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1268-1268.	0.9	0
233	Teaching Video Neuro Image :The â€œFonzarelliâ€•sign. Neurology, 2008, 71, e11.	1.5	0
234	Electrical impedance myography as a biomarker for ALS â€“ Author's reply. Lancet Neurology, The, 2009, 8, 227.	4.9	0

#	Article	IF	Citations
235	Neurogastroentrology: an A to Z. Practical Neurology, 2011, 11, 220-230.	0.5	0
236	An elusive cause for a progressive neuropathy. Practical Neurology, 2014, 14, 45-49.	0.5	0
237	The Role of Neuroimaging in Amyotrophic Lateral Sclerosis. , 2015, , 787-797.		0
238	Preface to â€˜Neuromythologyâ€™. Practical Neurology, 2016, 16, 315-315.	0.5	0
239	Motor neurone disease: not just motor and no longer one disease. British Journal of Neuroscience Nursing, 2016, 12, 214-215.	0.1	0
240	Clinic letters revisited. Practical Neurology, 2019, 19, 457-457.	0.5	0
241	MND plus. Practical Neurology, 2019, 19, 376-377.	0.5	0
242	Reply to: Early white matter changes on diffusion tensor imaging in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1266-1267.	1.7	0
243	Pineal gland as the source of the soul and third eye. Practical Neurology, 2022, 22, 168-169.	0.5	0